GENOMICTREE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20,150 KRW | -1.71% |
|
-3.36% | -2.18% |
| 2023 | Genomictree Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2022 | Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022. | CI |
Genomictree Inc. is a Korea-based company mainly engaged in the genomic analysis. The Company is involved in conducting of genomic analysis using microarrays and next generation sequencing analysis. In addition, the Company is conducting clinical trials for molecular diagnostic products. Molecular diagnostic products include cancer molecular diagnostic products and molecular genetic diagnostic products. Cancer molecular diagnostic products include molecular diagnostic products for colorectal cancer, bladder cancer, lung cancer, stomach cancer, cervical cancer. Molecular genetic diagnostic products include epidermal growth factor receptor (EGFR) mutation diagnosis, as well as human papilloma virus (HPV) diagnostic products.
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.18% | 357M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- A228760 Stock
- Funds and ETFs Genomictree Inc.
